Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brand: ZOLOFT
Published 2025-12-21 · Last reviewed 2025-12-28 · 4 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Sertraline (Zoloft) is a first-line SSRI for depression, PTSD, OCD, and anxiety disorders, favored in patients with serious mental illness because of modest interaction liability and metabolic neutrality.
Often paired with antipsychotics to target comorbid anxiety or depressive symptoms without exacerbating weight or prolactin issues.
Common early limitations include gastrointestinal upset, activation, and insomnia.
The compare view and the Sertraline evidence feed can help highlight activation, discontinuation, and metabolic trade-offs alongside the bipolar disorder hub when evaluating augmentation or switch strategies.
Low CYP inhibition and once-daily dosing support use alongside antipsychotics; monitor GI tolerability and sodium in older adults.
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Potent serotonin transporter inhibition with minimal direct activity at other receptors; weak dopamine transporter inhibition at high doses may contribute to activation.
Sertraline’s most common early barrier is GI upset; reassurance and supportive dosing strategies can prevent premature discontinuation before benefit emerges. Discontinuation symptoms can occur with abrupt stopping; tapering tends to be better tolerated than sudden discontinuation, especially after long-term use.